What Is Acromegaly and Why It's Hard to Diagnose

A Hormone Gone Wrong — After Growth Has Stopped

The human body is governed by a carefully balanced orchestra of hormones, and growth hormone is one of its most powerful instruments. In childhood and adolescence, it drives the dramatic changes that take us from infants to adults. But in a small number of people, this hormone keeps signaling long after development is complete — triggering a slow, relentless condition called acromegaly.

Acromegaly is a rare chronic disorder defined by excess growth hormone (GH) and its downstream messenger, insulin-like growth factor-1 (IGF-1), circulating in the blood of adults. Because the bones have already fused by adulthood, they cannot lengthen the way they do in children with similar hormonal excess. Instead, the skeleton — and soft tissues — grow wider and coarser: hands and feet swell, facial features coarsen, and internal organs enlarge.

What Causes It?

In more than 95% of cases, acromegaly is caused by a benign tumor called a pituitary adenoma — a growth on the pituitary gland, the pea-sized master gland at the base of the brain. The tumor produces excess GH, which in turn stimulates the liver to release IGF-1, causing abnormal tissue growth throughout the body. Rarely, the condition can originate from tumors in the lungs, pancreas, or elsewhere that secrete hormones mimicking pituitary signals.

Acromegaly affects an estimated 40 to 70 people per million worldwide, making it a genuinely rare disease. Most people receive a diagnosis in their forties or fifties — though the condition typically begins years, sometimes decades, earlier.

Recognizing the Signs

Acromegaly announces itself gradually, which is precisely what makes it so treacherous. Symptoms include:

• Enlarged hands and feet — rings that no longer fit, shoes that suddenly feel tight
• Coarsened facial features: a protruding brow, enlarged nose, widened jaw
• Thickened, oily skin and excessive sweating
• Deepening of the voice
• Joint pain and reduced mobility
• Headaches and vision problems (from the tumor pressing on nearby nerves)
• Fatigue and weakness

Because these changes occur over years rather than weeks, patients — and often their doctors — fail to notice them. A person may dismiss widening fingers as weight gain, or attribute a heavier brow to aging. According to research published in Pituitary, the average gap between symptom onset and diagnosis is four to eight years. In some cases, a decade passes before the correct diagnosis is made.

Why Diagnosis Is So Delayed

The diagnostic delay in acromegaly is one of medicine's stubborn frustrations. Two factors conspire against early detection: the disease's own stealth, and gaps in clinical awareness.

Because the condition is rare, most general practitioners may see only a handful of cases — or none — in an entire career. Patients are frequently told their changes are simply signs of aging. By the time the disease is caught, according to the National Institute of Diabetes and Digestive and Kidney Diseases, two-thirds of patients harbor a macroadenoma — a tumor larger than one centimeter that may already be pressing on surrounding brain tissue.

Diagnosis is confirmed through blood tests measuring IGF-1 levels, followed by an oral glucose suppression test: in healthy people, drinking a glucose solution suppresses GH; in acromegaly, it does not. MRI scans then locate the pituitary tumor.

Complications and Long-Term Risk

Untreated, acromegaly does far more than alter appearance. Excess GH disrupts nearly every organ system. Mayo Clinic lists the main serious complications:

• Cardiovascular disease: enlarged heart muscle (acromegalic cardiomyopathy), high blood pressure, arrhythmias
• Type 2 diabetes, because excess GH interferes with insulin signaling
• Sleep apnea, caused by soft tissue growth in the airway
• Arthritis and irreversible joint damage
• Colon polyps and an elevated risk of colorectal cancer

Without treatment, life expectancy can be shortened by roughly 10 years. With effective control of GH levels, most patients can achieve a near-normal lifespan.

How It Is Treated

The gold-standard treatment is transsphenoidal surgery — a minimally invasive procedure in which a neurosurgeon accesses the pituitary through the nose and nasal passages, removing the tumor without opening the skull. When surgery achieves complete removal, it can be curative.

When surgery is incomplete, or when the tumor is inaccessible, medication becomes the mainstay of management. Somatostatin analogs such as octreotide and lanreotide suppress GH secretion and are given as monthly injections. A newer drug, pegvisomant, blocks GH receptors directly. Radiation therapy is reserved for tumors that resist both surgery and medication.

The AI Frontier

Closing the diagnostic gap is a major research priority. In early 2026, scientists at Kobe University reported a breakthrough: an AI system capable of detecting acromegaly from photographs of the hand — a privacy-friendly alternative to facial imaging. Published in the Journal of Clinical Endocrinology & Metabolism, the study found the model outperformed experienced endocrinologists using the same images. Researchers envision such tools as a first-line screening aid, flagging at-risk patients for specialist referral and potentially cutting the decade-long diagnostic odyssey that still affects many patients today.